Laurus Labs Ltd
NSE:LAURUSLABS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
369.35
512.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LAURUSLABS stock under the Base Case scenario is 377.2 INR. Compared to the current market price of 512.6 INR, Laurus Labs Ltd is Overvalued by 26%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Laurus Labs Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LAURUSLABS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Laurus Labs Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Laurus Labs Ltd
Balance Sheet Decomposition
Laurus Labs Ltd
Current Assets | 38.3B |
Cash & Short-Term Investments | 115.3m |
Receivables | 16.6B |
Other Current Assets | 21.6B |
Non-Current Assets | 45.5B |
Long-Term Investments | 1.7B |
PP&E | 40.5B |
Intangibles | 2.7B |
Other Non-Current Assets | 678.5m |
Current Liabilities | 31.1B |
Accounts Payable | 10.5B |
Other Current Liabilities | 20.6B |
Non-Current Liabilities | 11.6B |
Long-Term Debt | 8.6B |
Other Non-Current Liabilities | 3B |
Earnings Waterfall
Laurus Labs Ltd
Revenue
|
50.5B
INR
|
Cost of Revenue
|
-23.9B
INR
|
Gross Profit
|
26.7B
INR
|
Operating Expenses
|
-22.9B
INR
|
Operating Income
|
3.8B
INR
|
Other Expenses
|
-2.3B
INR
|
Net Income
|
1.5B
INR
|
Free Cash Flow Analysis
Laurus Labs Ltd
INR | |
Free Cash Flow | INR |
Laurus Labs' Q2 FY '25 results reflected stable revenues of INR 1,224 crores, despite a flat growth year-over-year. While the CDMO division saw an 8% growth, this was offset by an 11% dip in generic API sales, particularly in oncology. The company's gross margins remained strong at 55%, while EBITDA margins were subdued at 15%. Looking ahead, Laurus is optimistic about achieving a full-year EBITDA margin of up to 20%, with growth anticipated from project deliveries in H2. New investments in a small molecule R&D center are expected to enhance capabilities and support future demand, affirming their commitment to advancing their offerings in the CDMO sector.
What is Earnings Call?
LAURUSLABS Profitability Score
Profitability Due Diligence
Laurus Labs Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Laurus Labs Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
LAURUSLABS Solvency Score
Solvency Due Diligence
Laurus Labs Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Laurus Labs Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LAURUSLABS Price Targets Summary
Laurus Labs Ltd
According to Wall Street analysts, the average 1-year price target for LAURUSLABS is 422.19 INR with a low forecast of 303 INR and a high forecast of 556.5 INR.
Dividends
Current shareholder yield for LAURUSLABS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
LAURUSLABS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The company is headquartered in Hyderabad, Telangana and currently employs 5,131 full-time employees. The company went IPO on 2016-12-19. The firm is a manufacturer of active pharmaceutical ingredients (API) for antiretroviral (ARV), oncology, cardiovascular, antidiabetics, anti-asthma and gastroenterology. The company also develops and manufactures oral solid formulations, which provide contract research and manufacturing services (CRAMS) to other global pharma companies, and produce specialty ingredients for nutraceuticals, dietary supplements and cosmeceuticals. The firm operates through four business units covering a range of therapeutic applications, including Generics API, which is engaged in the development, manufacture and sale of APIs and advanced intermediates; Generics Finished Dosage Form (FDF), which is engaged in the development and manufacture of oral solid formulations; Synthesis, which is a key starting materials, intermediates and APIs for New Chemical Entities (NCEs), and Bio, which is engaged in the recombinant products.
Contact
IPO
Employees
Officers
The intrinsic value of one LAURUSLABS stock under the Base Case scenario is 377.2 INR.
Compared to the current market price of 512.6 INR, Laurus Labs Ltd is Overvalued by 26%.